<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>51</viewCount><searchCount>0</searchCount></scores><additional><omics_type>Unknown</omics_type><volume>2011</volume><submitter>Spitzer P</submitter><pubmed_abstract>Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (A?42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and A?42.</pubmed_abstract><journal>International journal of Alzheimer's disease</journal><pagination>739847</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3227514</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia.</pubmed_title><pmcid>PMC3227514</pmcid><pubmed_authors>Klafki HW</pubmed_authors><pubmed_authors>Kamrowski-Kruck H</pubmed_authors><pubmed_authors>Spitzer P</pubmed_authors><pubmed_authors>Wiltfang J</pubmed_authors><pubmed_authors>Otto M</pubmed_authors><pubmed_authors>Parnetti L</pubmed_authors><pubmed_authors>Herukka SK</pubmed_authors><pubmed_authors>Chiasserini D</pubmed_authors><pubmed_authors>Schuchhardt J</pubmed_authors><pubmed_authors>Schieb H</pubmed_authors><view_count>51</view_count></additional><is_claimable>false</is_claimable><name>Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia.</name><description>Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (A?42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and A?42.</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011</publication><modification>2021-02-21T09:43:15Z</modification><creation>2019-03-27T00:46:34Z</creation></dates><accession>S-EPMC3227514</accession><cross_references><pubmed>22145083</pubmed><doi>10.4061/2011/739847</doi></cross_references></HashMap>